Welcome to Teva

Enabling people to live better, healthier lives

teva

Providing innovative and high-quality medicines

Serving 200 million people every day

Maintaining sales & operations in over 60 countries

Teva today

A strong specialty medicines portfolio

The leading global generic company

2017 revenues:
$22.4
billion

60 Markets &
80 manufacturing sites

Over the counter medicines & active pharmaceutical Ingredients (API)

45,000
employees

teva

Starting out in 1901 in Jerusalem

A story of entrepreneurship

Teva's history

1901 - 1940

A new pharmaceutical industry is founded

1901: Established in Jerusalem by Chaim Salomon, Moshe Levin and Yitschak Elstein.

1960 - 1980

Consolidation of the local pharmaceutical industry

1976: Eli Hurvitz forms Teva Pharmaceutical Industries Ltd.

1980 - 1990

Global expansion

1984: Hatch-Waxman Act paves way for U.S. generic entry
1987: Teva begins trading on NASDAQ

1990 - present

A global leader in generics / establishes specialty franchise

1996: Teva launches Copaxone® in the US.
2006: Teva acquires Ivax
2016: Teva acquires Actavis Generics

Highlights

- Leading Global Generic and Pharmaceutical Company
- Unique Late-Stage Specialty Pipeline
- Management Team with Strong Track Record
- Focus on Execution of Restructuring Plan

Generics

Providing access to the world’s largest medicine cabinet

World leader in generic medicines

1 in 7
Rx in the US

1000+
Launches in 2017

Top 3 position
in 25 markets

Strong Gx growth in
Japan and LatAm

550+
therapies

#1
in first-to-files

1 in 8
Rx in the UK

1800+
Molecules

teva

Teva saved the U.S. healthcare system

$259 billion over a decade*

Generics make up 89% of prescriptions dispensed in the U.S. but only 26% of total medicine spending

Generic drug savings provide health systems with the ability to make investments in tomorrow's new medicines

*Between 2007-2016; Based on Teva's generic market share and Association for Accessible Medicines, Generic Drug Access and Savings in the U.S., 2017.

teva

Teva's Competitive Advantage in Generics

- First-to-File Leadership in the US
  Largest and most valuable generic pipeline

- Vertical Integration
  Teva's API business provides early access and an advantage in the development of new products

- Broad R&D Capabilities, Resources and Technologies
  Complex technologies in transdermals, injectables, inhalation, rings/suppositories

- Global Regulatory and IP Skills and Expertise

Leveraging scale and enhancing our competitiveness

80
Manufacturing Sites in 33 countries

16,000
Products and 50,000 SKUs

120 Billion
Tabs/Caps

25,000
Employees in Operations

teva

Specialty

Creativity and innovation where it matters

Therapeutic areas of focus

Migraine and headache

Movement disorders and neurodegeneration

Pain

Respiratory

Our leading specialty brands

CNS

- AZILECT® Once-Daily (rasagiline tablets)
- Austedo™ (deutetrabenazine) 6 mg, 9 mg, and 12 mg tablets
- COPAXONE® (glatiramer acetate injection)

Respiratory

- ProAir RespiClick® (albuterol sulfate) Inhalation Powder
- QVAR® RediHaler™ (beclomethasone dipropionate HFA) Breath-Actuated Inhalation Aerosol 40 mcg • 80 mcg
- CINQAIR™ (reslizumab) injection
- DuoResp® Spiromax® budesonide/formoterol

Oncology

- BENDEKA™ (bendamustine HCl) injection
- GRANIX® (TBO-FILGRASTIM) Injection
- LONQUEX® lipegfilgrastim
- Trisenox® (arsenic trioxide) injection

teva

Central Nervous System Disorders

Focused on improving the health of patients

- COPAXONE® - relapsing-remitting multiple sclerosis (RRMS)
- AUSTEDO® - chorea associated with Huntington's disease and Tardive Dyskinesia
- Key research programs in migraine and headache, movement disorders and Huntington's disease

"He said he could actually sit and have a conversation with her without feeling like she was going to fall off of her chair due to her extra movement."

Migraine

- More than 1 billion people affected worldwide
- The third most prevalent illness in the world
- Significant medical need for migraine prevention
- Fremanezumab - successfully completed phase III trials for
  - Chronic Migraine
  - Episodic Migraine

Respiratory addressing unique patient needs

- Asthma
- COPD
- Novel delivery systems
- Targeted biologics

Patient-centric solutions

Spiromax/
Respiclick

Unique
Devices

CINQAIR/
CINQAERO

Biologics

Generics

Generic
Advair

Services

Technology

TEVA SUPPORT SOLUTIONS

Leveraging
the model

Smart Inhaler
Connectivity

Teva in Israel

Sites in Israel

Jerusalem - Inhalers and oral solid, 800 employees

Kfar Saba - oral solid and sterile, GR&D, 1500 employees

Shoham - Logistic center and Teva Israel, 600 employees

8 sites in Israel produce annually:

- 9 billion tablets and capsules
- 4 million inhalers
- 21 million TevaDaptor units

Teva’s largest operations center

3,000

workforce

Exporting from Israel to 60 markets

Shoham logistic center:
one of global pharma's largest

Israel footprint

Supporting
21,000 jobs

$4B
in investments
over a decade

$27B
in exports in the
past 5 years

1 in 5

prescriptions in Israel is for a Teva product

Innovative Pharma & Branded Rx

Generics

OTC

In Israel: diverse leadership

- #1 in dialysis equipment
- #1 in genetic pregnancy tests
- **6000** Daily logistic supply points
- #1 in generics #1 in specialty #1 in OTC
- Pioneers in genetic diagnostics
- Active in all therapeutic areas
- Own variety of Super Brands
- #1 in IV
- Active in baby formula market
- Leading in home-care treatment

Investing in digital health start ups

SANARA VENTURES

PHILIPS

TEVA

Strategic partnership with Philips - Incubator for investment in startups

My HomeDoc

My HomeDoc develops an affordable solution for remote checkups and diagnosis anywhere based on a smartphone.

Breathe.me

Breathe.me develops an ultra-low cost Asthma/COPD monitoring & management solution, using an acoustic sensor and mobile application for lung function testing.

teva

Thank you!

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc's worldwide generic pharmaceuticals business; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and increased regulation; delays in launches of new generic products; our ability to take advantage of high-value biosimilar opportunities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; the difficulty and expense of obtaining licenses to proprietary technologies; returns, allowances and chargebacks; and investigations of the calculation of wholesale prices;

our specialty medicines business, including: competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;

our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;

compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;

other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned "Risk Factors," and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.